To date, AAV vectors have been used in over 117 clinical trials worldwide, approximately 5.6% of virus-vectored gene-therapy trials.[13] Recently, promising results have been obtained from Phase 1 and Phase 2 trials for a number of diseases, including Leber's congenital amaurosis,[3][14][15] Hemophilia,[16] congestive heart failure,[17] spinal muscular atrophy,[18] lipoprotein lipase deficiency[citation needed], and Parkinson's disease.[19]